Schrödinger: Turbo for Drug Discovery! Schrödinger Bets on AI Agent Bunsen and Major Partners!
Reading Time: 3 minutes
The "Healthcare" sector is considered an area where AI will have a significant impact on the speed of development. Schrödinger is already starting to unlock this potential with its initial tools and was able to gain over 55% last month. We want to present the company in more detail and examine the highlights from recent times. Schrödinger is working on its simulation software for drug discovery AI agent Bunsen is being widely used at Bristol Myers Squibb Annual contract value rises by 27% to $29.6 million in Q2 2026 Schrödinger Inc....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
